Mu and colleagues describe a JAK–STAT signaling-dependent transition to a stem-like, multilineage state that is resistant to prostate cancer AR therapy and propose combinatorial targeting of JAK–STAT proteins to resensitize resistant tumors. Here, SOAT1 is linked to Familial prostate cancer.